On October 16, 2026, Novartis AG (NYSE: NVS) announced it is discontinuing enrollment in its mid-stage clinical trial for Fabhalta (iptacopan), an oral Factor B inhibitor targeting lupus nephritis, citing strategic reasons. This decision comes despite Fabhalta generating approximately $505 million in sales last year, supported by strong growth momentum.
Novartis' decision to halt enrollment in the Fabhalta lupus nephritis trial marks a notable pivot in its clinical development strategy. The study, which involved 81 patients assessing Fabhalta's efficacy alongside standard care, will no longer accept new participants. While the company cited strategic reasons rather than safety or efficacy concerns, this move may reflect a reallocation of resources toward other pipeline priorities or market dynamics. Fabhalta remains a commercial success, having achieved $505 million in sales last year with over 150% year-over-year growth in Q4 adjusted for currency fluctuations, underscoring its importance to Novartis' immunology portfolio.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.